Zantac lawsuit drop ‘not as significant as it appears’ for GSK stock, analysts say
The withdrawal of a plaintiff in GSK's first Zantac lawsuit but may not be “as significant as it appears”, say analysts from RBC Europe.
0.32 | |
0.32 | |
800 | |
0.32 | |
0.32 | |
0 - 0 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
The withdrawal of a plaintiff in GSK's first Zantac lawsuit but may not be “as significant as it appears”, say analysts from RBC Europe.
Sanofi was upgraded to hold from sell at Deutsche Bank, after the heavy selling over the previous two days on worries about Zantac heartburn medication litigation. The first trial is set to begin on Aug. 22. "We think the Zantac knee-jerk is starting to look somewhat overdone. This doesn't make for ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: